Wegovy maker Novo Nordisk down 4%, heads for worst day since October
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
